"We are pleased that we have succeeded in attracting new high quality investors like Wellington Partners in our Series B round. This clearly signals backing from our investor community for the intended merger with Arpida."
Neil Goldsmith
CEO, Evolva
Wellington contact:
Erich Schlick
| Developing drugs with genetic chemistry |
Evolva uses its proprietary genetic chemistry platform to replicate the ability of nature to create small molecules with exquisite design on an industrial basis. Based on this technology, Evolva has a number of discovery and pre-clinical partnerships which in 2008 generated revenues of about CHF 12 million. Evolva also has an attractive pipeline of drug candiates deriving from this approach – one compound (for renal and cardiovascular disease) entered Phase I beginning of 2009, and two others (an anti-fugal and an anti-viral) are expected to enter Phase I in 2010. The company expects to progress these candidates through phase II proof-of-concept clinical trials over the next 2 to 3 years. The combination of an extraordinary platform and exciting novel products has convinced Wellington Partners to co-lead a Series B round in autumn 2009 together with existing and further new investors. This financing round was also a prerequisite for the planned reverse merger with listed Swiss biotech company Arpida.
First investment: October 2009
Evolva SA
Hagmattstrasse 6
CH-4123 Allschwil
Switzerland
